Doc Summary
Dec 27 (Reuters) – BioNTech (22UAy.DE), opens new tab has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University of Pennsylvania over the payment of royalties related to its COVID-19 vaccine, the company said in filings.
The German company, which partners with U.S. drugmaker Pfizer (PFE.N), opens new tab for its COVID-19 vaccine, said on Friday it would pay $791.5 million to the U.S. agency to resolve a default notice.
